Although sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated hepatic benefits in diabetic populations, their role in non-diabetic individuals with NAFLD remains unclear. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.